ISRG

Business Context and Reporting Period

Company: Intuitive Surgical, Inc. (ISRG)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Intuitive Surgical develops, manufactures, and markets the da Vinci surgical systems and the Ion endoluminal system. The company operates as a single reportable segment, providing a comprehensive ecosystem of robotic-assisted surgical platforms, instruments, accessories, learning, and services to advance minimally invasive care. The company is headquartered in Sunnyvale, California, and operates globally with significant manufacturing in the U.S., Mexico, Germany, and China.

Key Financial Metrics

Note: The company maintains a debt-free balance sheet. Total liabilities were $2.52 billion, primarily consisting of accrued compensation, deferred revenue, and other operating liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 21% to $10.06 billion, driven by a 19% increase in instruments and accessories revenue ($6.02 billion) and a 26% increase in systems revenue ($2.47 billion).
• Procedure Volume: Approximately 3.15 million da Vinci procedures were performed in 2025, an 18% increase from 2024. Ion procedures grew 51% to approximately 144,100.
• System Placements: Total da Vinci system placements increased 13% to 1,721 units, including 870 da Vinci 5 systems (up from 362 in 2024). The installed base grew to approximately 11,106 systems.
• Margin Compression: Gross profit margin decreased to 66.0% from 67.5%. Management attributed this to new tariffs (increasing costs by approximately $63 million in 2025), incremental fixed overhead costs from expanded manufacturing capacity, and higher costs associated with the da Vinci 5 system.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 11% to $2.39 billion, and R&D expenses rose 15% to $1.31 billion, driven by higher headcount, share-based compensation, and a $70 million charitable contribution to the Intuitive Foundation.

Guidance, Outlook, and Risks

Outlook and Commentary:

• Tariffs: The company expects cost of revenues driven by tariffs and trade measures to continue to increase in 2026, assuming current tariffs remain in place. Tariffs impacted costs by $63 million in 2025.
• Depreciation: Depreciation expense is expected to continue to increase in 2026 due to capital expenditures made in 2024 to scale infrastructure.
• China Operations: System placements in China were lower than anticipated in 2025 due to a government anti-corruption campaign, increased competition from domestic manufacturers, and industrial policy measures. The impact remains uncertain.
• Product Launches: The company continues the phased launch of the da Vinci 5 system globally and the da Vinci SP system. New regulatory clearances were obtained for the da Vinci 5 in Japan and the EU, and for the da Vinci SP in the U.S. for additional procedures.

Key Risks and Contingencies:

• Regulatory Environment: Risks include delays in FDA or foreign regulatory approvals, potential enforcement actions, and changes in healthcare reimbursement policies (e.g., limits on robotic surgery charges in certain Chinese provinces).
• Competition: Increasing competition in China and globally from domestic and international robotic surgery companies. Competition from weight-loss drugs has reduced bariatric procedure volumes.
• Supply Chain: Reliance on sole- and single-sourced suppliers and potential disruptions from trade barriers or geopolitical conflicts (e.g., rare earth element export controls from China).
• Legal Proceedings: Ongoing product liability litigation and antitrust claims (e.g., In Re: da Vinci Surgical Robot Antitrust Litigation) which could result in significant costs or reputational harm.
• Usage-Based Leasing: Increased exposure to credit risk and revenue volatility due to the growing proportion of usage-based operating lease arrangements.

Investor Verification Checklist

• Tariff Impact: Verify the specific magnitude of tariff impacts on 2026 margins and whether the company plans to pass costs to customers.
• China Market Dynamics: Monitor the resolution of the anti-corruption campaign and tender processes in China, as well as the competitive landscape from local manufacturers.
• da Vinci 5 Adoption: Track the conversion rate of older systems to the da Vinci 5 and the associated impact on average selling prices (ASPs) and trade-in volumes.
• Leasing Mix: Assess the growth of usage-based operating leases and the associated credit risk exposure, particularly given hospital financial pressures.
• Antitrust Litigation: Review the status of the Ninth Circuit appeal in the SIS antitrust case and the class certification in the In Re: da Vinci litigation.
• Reimbursement Policies: Monitor changes in reimbursement rates in key markets (Japan, EU, China) and the impact of the EU Health Technology Assessment (HTA) regulation.